Organization | Associacao Fundo de Incentivo a Psicofarmcologia

Associacao Fundo de Incentivo a Psicofarmcologia Report issue

Academic/Hospital Phase 3 Phase 4

Founded: Sao Paulo Brazil (1976)

Organization Overview

First Clinical Trial

1999

NCT00480870

First Marketed Drug

None

First NDA Approval

None

Last Known Activity

2013

Timeline

NOW

Now

Active Ingredients

Drugs in Phase 4 Trials (2)

donepezil (aricept) (2 trials)

zolpidem (ambien) (1 trial)

Drugs in Phase 3 Trials (2)

naltrexone (revia) (1 trial)

polyunsaturated fatty acids (1 trial)

Drugs in Other Trials (3)

azelaic acid (azelex) (1 trial)

drospirenone (Yasmin) (1 trial)

ethinyl estradiol (Estinyl) (1 trial)

Indications

Experimental Indications (Clinical Trials, Phases 1-4)

Alcoholism (Phase 3)

Alzheimer Disease (Phase 4)

Apnea (Phase 4)

Sleep Apnea, Obstructive (Phase 4)

Sleep Apnea Syndromes (Phase 4)

Sleep Initiation and Maintenance Disorders (Phase 4)

Overview

Highest Phase: Phase 4
# of Trials: 5
# of Trial APIs: 7